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Testosterone deficiency (TD) is a well-established and significant 
medical condition.1,2 It has been defined as a clinical and biochemical 
syndrome, associated with older age and comorbidities.3 It is 
characterised by a deficiency in serum androgen levels, with or without 
reduced genomic sensitivity to androgens.2 The latter relates to the 
functionality of androgen receptors. For example, if there is CAG repeat 
polymorphism on exon 1 of the androgen receptor gene, the response 
to any given serum testosterone (T) concentration is reduced as the 
number of CAG repeats increases.4–8 
Biochemical TD must be associated with relevant signs and symptoms 
for a diagnosis to be made. The hormone has important physiological 
functions and deficiency can adversely affect the brain, peripheral 
nerves, muscle, fat, bone, the cardiovascular (CV) system and 
especially the male genital and reproductive systems. T is important 
for the regulation of carbohydrate metabolism, lipids and proteins, and 
positively affects glucose control, liver fat, cardiac biomarkers, muscle 
growth and adipogenesis.1,9–15 
Epidemiology
Epidemiological studies vary regarding the prevalence of TD. Perhaps 
the most useful study is the European Male Ageing Study, which 
evaluated more than 3,000 men between the ages of 40 and 79 
years, recording biochemistry results and symptoms. An overall 
prevalence of 2.5% was reported and rates varied from 0.1% in men 
aged 40–49 years to 5.1% in those aged 70–79. In this study, TD was 
defined as three or more sexual symptoms associated with a total 
T (TT) level <11 nmol/l and a free T (FT) level less than 0.22 nmol/l.16 
Three-quarters of men maintained normal T levels into old age. Based 
on biochemical levels, the prevalence of secondary TD was 11.8%, 
primary TD 2.0% and compensated (subclinical) TD 9.5% (worthy of 
observation but not treatment).17 
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Aetiology
Normal T levels depend on a healthy hypothalamic–pituitary–
gonadotropin axis. Primary TD results from disruption at the level of the 
testes, secondary TD from disruption at the level of the hypothalamus 
and pituitary and combined TD from disruption at both these levels.3 
Secondary TD is the most common form.17,18 
Pituitary tumours can cause centrally mediated TD. Primary testicular 
failure may result from orchitis, Klinefelter’s syndrome, chemotherapy 
or radiation. Additional causes of TD include obesity, diabetes, 
metabolic syndrome, HIV infection, chronic renal failure, and chronic 
glucocorticoid and opioid use.19,20 
Making the Diagnosis
The signs and symptoms of TD are shown in Table 1. Sexual symptoms 
are the most common, but there are many less specific symptoms 
such as fatigue, sleep disturbance, visceral obesity, loss of physical 
strength, decreased muscle mass, decreased energy and motivation, 
hot flushes, changes in cognition and memory, depression and 
decreases in bone mineral density.1–3,21–23 
The patient should be asked if they are taking any medications – 
prescription or otherwise – that can lower T levels, e.g. corticosteroids 
or opiates, or drugs that can cause erectile dysfunction (ED), and if they 
have previously taken T therapy.1,21
Physical examination should include height, weight, BMI and waist 
circumference, together with an assessment of body hair, any 
significant breast enlargement and the appearance of the penis and 
testicles.1,21,22,24 A prostate examination is also recommended.1,21 
The British Society for Sexual Medicine (BSSM) recommendations 
for case finding are to test for TD in adult men with persistent 
and multiple signs of TD and to screen for TD in all men presenting 
with ED, loss of spontaneous erections or low sexual desire, 
type 2 diabetes (T2D), BMI >30 kg/m2 or waist circumference 
>102 cm and those on long-term opiate, antipsychotic or 
anticonvulsant medications.1 
T has a diurnal rhythm in younger men, which may become less 
marked with age but not invariably so.22 Thus, the recommendation is 
to measure T between 7 am and 11 am on at least two occasions, with 
a reliable method, preferably 4 weeks apart and, if possible, not during 
an acute illness.1 A fasting sample is generally advised because T levels 
are influenced by insulin and glucose, and this is particularly important 
for the second test.25 If the first result was close to the lower normal 
range (8–12 nmol/l), it is advised to include levels of sex hormone 
binding globulin (SHBG).1 
The bioavailable forms of T are those not bound to SHBG, known as 
FT, and this may provide the most reliable clinical androgen status in 
some patients.16 
FT may be calculated using the equation of Vermeulen et al.26 Online 
FT calculators are provided by the International Society for the Study 
of the Aging Male (ISSAM), available at: http://issam.ch/freetesto.htm 
and the Primary Care Testosterone Advisory Group (PCTAG), available 
at: http://www.pctag.uk/testosterone-calculator/. Reference ranges 
quoted by laboratories represent the normal population and these 
are often much lower than the advised action levels recommended 
by the various guideline groups. 
The BSSM and International Society for Sexual Medicine (ISSM) 
recommend the following action levels:1,27 
• TT less than 8.00 nmol/l, or FT less than 0.18 nmol/l (based on two 
separate levels taken between 8 am and 11 am) usually requires 
T therapy.
• TT higher than 12.00 nmol/l, or FT higher than 0.225 nmol/l does 
not require T therapy.
• TT levels between 8.00 nmol/l and 12.00 nmol/l may require a trial 
of T therapy, for a minimum of 6 months, according to symptoms. 
The BSSM and ISSAM also recommend the following:1,22 
• Increased luteinising hormone (LH) levels and T levels below 
normal or in the lower quartile range indicates testicular failure, so 
T therapy should be considered.28 
• Men with increased LH levels, normal T levels but TD symptoms 
should be considered to have TD. 
European Male Ageing Study data demonstrated that clinical symptoms 
were more closely related to calculated FT than TT.29 
Testosterone Levels in Men
Ruige et al. demonstrated that higher T levels were associated with a 
decreased risk for CV events in men aged >70 years (HR 0.84; 95% CI 
[0.76–0.92]) but this was not the case in younger men (HR 1.01; 95% 
CI [0.95–1.08]).30 
Araujo et al. performed a meta-analysis that included 18 studies and 
more than 22,000 subjects and concluded that both overall and CV 
mortality were related to T levels.31
Corona et al. comprehensively reviewed 1,178 articles and included 70 
in their meta-analysis. They demonstrated a clear association between 
Table 1: Clinical Signs and Symptoms Suggestive of 
Testosterone Deficiency1–3,21–23
Sexual Physical
Delayed puberty Decreased body hair
Small testes Gynaecomastia
Infertility Decreased muscle mass and strength
Decreased sexual desire and  
activity
Hot flushes or sweats
Erectile dysfunction Sleep disturbances
Delayed ejaculation Fatigue
Decreased volume of ejaculate Osteoporosis/height loss/low-trauma 
fractures
Decreased or absent morning/
night-time erections
Cardiometabolic Psychological
Increased BMI/obesity Changes in mood, e.g. anger, irritability, 
sadness, depression
Visceral obesity Decreased wellbeing or poor self-rated 
health
Metabolic syndrome Decreased cognitive function (including 
impaired concentration, verbal memory and 
spatial performance)
Source: Hackett et al. 2017.1 Reproduced with permission from Elsevier. 
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low T/high oestradiol levels and CV disease (CVD). They made the point 
that longitudinal studies demonstrated that overall mortality and CV 
mortality were highest in those with lowest T levels.32
Coronary Artery Disease and Testosterone 
Deficiency
Clinical studies show favourable effects of short- or long-term exposure 
to T therapy on coronary and peripheral vasomotion and peripheral 
arterial stiffness.33–35 Physiological concentrations of intracoronary T 
cause epicardial coronary artery dilatation and increases in volume 
blood flow in men with coronary artery disease (CAD).33
T therapy in hypogonadal men delays time to ischaemia, improves 
mood and is associated with potentially beneficial reductions 
in biomarkers, total cholesterol and serum tumour necrosis 
factor-alpha.13,36 
Three early randomised, placebo-controlled trials demonstrated that 
administration of T improves myocardial ischaemia in men with CAD. 
All three trials found that in men with CAD, T prolongs the time to 
exercise-induced ST-segment depression as measured on treadmill 
stress testing.37–39
Numerous studies have demonstrated a negative correlation 
between endogenous T levels and intima-media thickness of the 
carotid arteries, abdominal aorta and thoracic aorta, which suggests 
that men with lower levels of endogenous T may be at a higher risk 
of developing more generalised atherosclerosis.40–47 Evidence also 
suggests that men with lower T levels are more likely to develop CAD 
during their lifetime and CAD severity has been shown to correlate 
with the degree of TD.48–55
Budoff et al. studied 170 T deficient men over the age of 65 years 
in a double-blinded, placebo-controlled trial setting in the US.56 
Men with symptoms suggestive of hypogonadism were enrolled in 
the study between June 2010 and June 2014. Treatment was with 
T gel, with the dose adjusted to maintain the T level in the normal 
range for young men, or placebo gel for 12 months. Plaque volume 
was determined by coronary CT angiography. For the primary 
outcome, T therapy compared with placebo was associated with a 
significantly greater increase in non-calcified plaque volume from 
baseline to 12 months. There were no major adverse CV events in 
either group. 
The authors point out that this trial had several strengths, 
including a placebo-controlled design, selection of men with 
unequivocally low T and a relatively high retention rate. However, they 
also point out that the study had some limitations. The assumptions 
about the composition of plaque components as detected by 
coronary CT angiography were not confirmed by direct radiological 
and pathological studies. Furthermore, the volume and radiological 
characteristics of coronary artery plaques are only surrogate outcomes 
and do not account for other factors that can influence the frequency 
and extent of plaque rupture and thrombosis. In fact, T therapy was 
associated with a significant increase in the volume of fibrous plaque, 
which may be more stable than other types of plaque. The major 
limitation is that the trial was not large enough or long enough to draw 
conclusions about the risk of T therapy on major adverse CV events. 
Larger studies are needed to understand the clinical implications of 
this finding.
All-cause Mortality, Cardiovascular Mortality and 
Testosterone Deficiency
Long-term studies, reviews and meta-analyses have supported 
the association between TD and increased all-cause and CV 
mortality.2,30,31,57–60 
A meta-analysis by Araujo et al. included 12 studies involving more than 
17,000 participants. Although there was considerable heterogeneity 
in these studies resulting from study and subject characteristics, 
low endogenous T levels were associated with both overall and 
CV mortality.31 
Corona et al. included 70 papers in their meta-analysis and showed a 
clear association between low T/high oestradiol levels and increased 
risk of CVD and CV mortality.32 
Muraleedharan et al. studied 581 men with T2D who were followed up 
for a mean of 5.8 years. Low T was defined as less than 10.4 nmol/l. 
A total of 51 men received T therapy for at least 2.0 years. Mortality 
rates were 20.0% in the low T group versus 9.1% in the normal T group, 
independent of comorbidities and other therapies, and T therapy 
reduced mortality similar to the controls.58 
Daka et al. demonstrated that low concentrations of T predicted acute 
MI in men with T2D.60 
Yeap et al. studied 3,690 older men over 10 years, TT and FT levels 
in the normal range were associated with reduced all-cause and CV 
mortality. Interestingly, both low and high levels of T were associated 
with all-cause mortality, and higher levels of dihydrotestosterone 
reduced ischaemic heart disease mortality.59 
A review by Muraldeedharan et al. raised the issue that these studies 
do not prove a pathogenic link, but low T may simply be a marker 
of illness.61
Testosterone Therapy and Cardiovascular Risk
T therapy has been controversial, with worries that treatment will 
increase CV risk. An extensive review of the literature published 
between 1940 and 2014 found only four studies that reported 
increased CV risk.62 The authors concluded that two of these were 
retrospective analyses with serious methodological limitations; one 
was a prospective trial with only four major adverse CV events and the 
other a meta-analysis that was criticised for using few studies and CV 
endpoints of questionable clinical importance, e.g. non-specific ECG 
findings and palpitations.63–66 
The study by Vigen et al. was indeed retrospective, involving 8,709 
men with a baseline TT level no higher than 10.4 nmol/l.63 These men 
were undergoing angiography and were followed up for a mean of 840 
days. Results showed 681 of the 7,486 patients who did not receive T 
therapy died, 420 had a MI and 486 had a stroke. Of the remaining 1,233 
patients receiving T therapy, only 67 died, 23 had a MI and 33 had a 
stroke. The authors then performed a complex statistical analysis using 
more than 50 covariates and concluded that there was a greater risk in 
the T therapy group. Some 1,132 patients were excluded because they 
were prescribed T therapy after the event when they should have been 
included in the untreated group, which falsely increased the events by 
70%. When challenged, the investigators revised the number to 132 but 
admitted that 104 women had been mistakenly included in the results. 
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Worryingly, there were no data confirming the correct diagnosis of TD 
syndrome or T therapy and duration of therapy.62
The Finkle et al. study provided prescribing data in men treated 
with T, but there were no records of T blood results or the patients’ 
symptoms.64 The researchers defined non-fatal coronary events as the 
major endpoint assessed in the 12 months before and 3 months after 
therapy. This is clearly a major weakness because the benefits of T 
therapy would take longer than this to appear and many other studies 
have excluded the first 3 months of treatment from analysis because 
of the likelihood of events relating to the pre-existing condition. In 
addition to this, data on fatal CV events and all-cause mortality were 
not collected and 12-month post-treatment data were collected but 
not presented. The lack of mortality data fails to recognise that any 
treatment that decreases mortality is, of course, likely to increase non-
fatal events. The design was not prospective and although used as 
evidence against T therapy, it has been discredited by several design 
flaws and statistical analyses.62 
Following these publications, in January 2014 the US Food and Drug 
Administration (FDA) convened an advisory committee meeting to 
review CV risks of T therapy. Subsequently, the FDA expanded the 
stated purpose of this committee to include a review of the suitable 
populations for T therapy. On 17 September 2014, the advisory 
committee voted to restrict therapeutic indications for T therapy and 
requested that the pharmaceutical industry perform a CV safety study. 
In March 2015, all US commercial T products underwent a mandatory 
label change that restricted the indicated population and warned 
against the possible risk of MI and stroke.67 
The EU and Health Canada also issued warnings regarding T therapy 
and potential CV risk. A review by the European Medicines Agency’s 
Pharmacovigilance Risk Assessment Committee recommended 
updating the product information warning about the potential 
increased CV risk in hypogonadal men using T therapy, but did not 
confirm an increase in heart problems with T medicines.68 These label 
changes have led to significant media coverage, which is ongoing. 
Testosterone Therapy and Decreased 
Cardiovascular Risk
There are more than 100 studies showing CV benefits of higher 
endogenous T levels or improved CV risk factors with T therapy.69 
This may not be surprising because long-term T therapy reduces fat 
mass, increases lean mass, improves glycaemic control, reduces 
insulin resistance and waist circumference and improves the ability 
to exercise.
In a retrospective observational study involving 1,031 hypogonadal 
men aged over 40 years, 398 of whom took T therapy, the cumulative 
mortality was 21% in the untreated group versus 10% in the treated 
group (p<0.0001). The mortality rates were 3.4 deaths per 100 person-
years for T-treated men and 5.7 deaths per 100 person-years in men 
not treated with T. The greatest effect was observed in younger men 
and those with T2D.70 
In a prospective study, 581 men with T2D and low T (defined as 
TT <10.4 nmol/l) were followed up for a mean of 5.8 years. Fifty-one men 
were treated for at least 2.0 years. Mortality rates were 20.0% in the low 
T group versus 9.1% in the normal T group, independent of comorbidities 
and therapies, and 9.4% in those with TD in the treated group.58 
Both studies demonstrated that mortality was reduced by approximately 
half in those who received T therapy compared with those who did not. 
A retrospective study followed up 857 men with T2D for 4 years after 
baseline T measurements. Patients were randomised to long-acting T 
undecanoate or placebo. Low baseline TT and FT levels were associated 
with increased all-cause mortality. T therapy and phosphodiesterase 
type 5 (PDE5) inhibitor use were independently associated with lower 
all-cause mortality (Figures 1–4).71 Interestingly, the greatest benefits 
from the two treatments were seen in older men (Figure 5).72 
This finding regarding PDE5 inhibitor treatment was supported by two 
database studies demonstrating CV and mortality benefits.73,74
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Figure 1: Men Stratified by Testosterone Replacement 
Therapy
The estimated mortality probability and 95% CI from the fitted logistic regression: men 
stratified by testosterone replacement therapy. T = testosterone. Source: Hackett et al. 2017.71 
Reproduced with permission from Baishideng Publishing Group.
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Figure 2: Men Stratified by Phosphodiesterase Type 5 
Inhibitor Treatment
The estimated mortality probability and 95% CI from the fitted logistic regression: men 
stratified by testosterone replacement therapy. PDE5 = phosphodiesterase type 5. Source: 
Hackett et al. 2017.71 Reproduced with permission from Baishideng Publishing Group. 
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Registry data provide useful evidence where parenteral T undecanoate 
was used for up to 10 years in 656 men with a mean age of 60.7 years. 
Long-term treatment was well tolerated, with excellent adherence. 
Importantly, mortality related to CVD was significantly decreased in the 
group taking T versus the untreated group.75
A large retrospective study examined 83,010 male veterans with low TT 
levels who were categorised into three groups:76
• group 1: T therapy resulting in normalisation of T levels; 
• group 2: T therapy without normalisation of T levels; and 
• group 3: did not receive T therapy. 
All-cause mortality (HR 0.44; 95% CI [0.42–0.46]), risk of MI (HR 0.76; 
95% CI [0.63–0.93]) and stroke (HR 0.64; 95% CI [0.43–0.96]) were 
significantly lower in group 1 (n=43,931, median age 66.0 years, mean 
follow-up 6.2 years) than group 3 (n=13,378, median age 66.0 years, 
mean follow-up 4.7 years). Similarly, all-cause mortality (HR 0.53; 95% 
CI [0.50–0.55]), risk of MI (HR 0.82; 95% CI [0.71–0.95]) and stroke (HR 
0.70; 95% CI [0.51–0.96]) were significantly lower in group 1 than group 
2 (n=25,701, median age 66.0 years, mean follow-up 4.6 years). There 
was no difference in the risk of MI or stroke between groups 2 and 3.76 
A further large study compared acute MI rates in 6,355 men aged 66 
years and older who received at least one T injection, compared with 
a matched placebo group over an 8 year period. It found no overall 
increase in events, those at greatest risk experienced a significant 
reduction in events and mortality and there was no increased risk from 
thromboembolism.77 
A virtual controlled study examined electronic medical records from 
1996 to 2011 to identify 5,695 men who had a low initial TT level, a 
subsequent T level and up to 3 years of follow-up. It demonstrated a 
positive impact of T therapy – particularly on mortality – and there was 
no suggestion of increased risk with sustained higher serum levels.78 In 
a more recent study, the same group reported a significant reduction 
in CV events in a cohort of hypogonadal men with angiographically 
confirmed CAD.79 
Wallis et al. compared 10,311 T-treated men with 28,029 controls. 
They found a reduction in all-cause and CV mortality with T therapy. 
They also found an increase in mortality in the first 6 months 
compared with normal, which was attributed to the impact of 
underlying undertreated TD. Reassuringly, this study also reported 
a 40% reduction in new diagnoses of prostate cancer in the treated 
group versus the control group.80 
Lastly, a study comparing 8,808 T-treated men with 35,527 untreated 
men with low T reported a 33% reduction in cardiac events associated 
with T therapy.81 
These results corroborate those of registry studies, which have 
published data collected over 6 years of follow-up, with no suggestion 
of increased mortality.82 
Heart Failure 
TD is common during the course of chronic heart failure (CHF). 
Reduction in circulating T level predicts a deterioration of functional 
capacity and suggests a role for managing TD in CHF. T is a determinant 
of exercise capacity, muscle mass and strength. TD is involved in 
the pathophysiology of CHF, contributing to some features of this 
syndrome such as reduced muscle mass, abnormal energy handling, 
fatigue, dyspnoea and, ultimately, cachexia.83–85
Approximately 25% of patients affected by CHF have T levels below 
normal ranges and this is related to disease progression. In addition, 
reduction of circulating T levels may contribute to some specific 
features of CHF, such as abnormal energy handling, weakness, 
dyspnoea and cachexia in particular. T therapy may improve muscle 
strength and functional pulmonary capacity in (CHF) in men with TD.86
Jankowska et al. studied 208 men with CHF and 366 healthy male 
controls.87 Low T levels were found in all New York Heart Association 
(NYHA) classes of heart failure. It has also been shown that reduced T 
levels in men with CHF indicates a poor prognosis and is associated 
with increased hospital admissions and mortality.88,89 
A meta-analysis of a small number of randomised controlled trials 
studied the effect of T therapy on exercise capacity in HF patients.90 
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Figure 3: Long-term Mortality Data in Diabetes
Long-term mortality data in diabetes: the BLAST long-term study (n=857). Source: Hackett  
et al. 2017.71 Reproduced with permission from Baishideng Publishing Group.
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Figure 4: Men on All or No Treatments
The estimated mortality probability and 95% CI from the fitted logistic regression comparing 
men on all three treatments (testosterone, phosphodiesterase type 5 inhibitor and statin) and 
on none of the treatments. Source: Hackett et al. 2017.71 Reproduced with permission from 
Baishideng Publishing Group. 
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The four studies (n=198; men, 84%; mean age 67 years) tested either 
transdermal or intramuscular T, given between 12 weeks and 12 months. 
The endpoints were 6-minute walk test (6MWT), incremental shuttle 
walk test, or peak VO2 by cardiopulmonary exercise test. The 6MWT 
increased by 54.0 metres, incremental shuttle walk test increased by 
46.7 metres, and peak VO2 increased by 2.7 ml/kg/min in the T-treated 
patients versus placebo. The increase in peak VO2 and distance walked 
in the T-treated group correlated with the increase in FT. 
This degree of improvement in the 6MWT is similar to that seen 
with other therapies in patients with HF. The NYHA functional class 
improved by ≥1 grade in 9.8% of patients in the placebo group versus 
35.0% of patients in the T therapy group. There were no significant 
differences in major adverse cardiac events between the T therapy 
and placebo groups.90
Concern About Prostate Cancer
There is no compelling evidence that T therapy is associated with 
an increased risk of prostate cancer. This statement is supported 
by guidelines from the European Association of Urology, the BSSM, 
the International Consultation on Sexual Medicine (ICSM) and the 
ISSM.1,3,21,23 The ISSAM states that there is no evidence that T therapy 
converts subclinical prostatic lesions into clinically detectable prostate 
cancer, and the ICSM states that there is no compelling evidence that 
T therapy is associated with prostate cancer progression.3,22
T therapy may make occult prostate cancer cases detectable within 
an early phase of treatment and present a beneficial effect in relation 
to early detection. Future longitudinal studies are needed to confirm 
these findings.91
Testosterone Therapy
The choice of therapy lies between the transdermal route and 
long-acting T undecanoate injection, depending on patient choice. 
Adverse events related to T therapy are relatively rare, but follow-up 
is important because T therapy – especially shorter-acting injections – 
can increase the haematocrit.92 
In patients with TD, ischaemia should be addressed wherever possible 
and underlying risk factors corrected. Mathur et al. tested the effect 
of T therapy on ischaemia during 12 months of treatment.93 Long-term 
treatment with T increased time to develop ischaemia on a treadmill 
(129 seconds in T patients versus 12 seconds in placebo patients, 
p=0.020).
Nevertheless, it would seem sensible to be cautious in patients with 
CVD in an unstable state and approach replacement therapy in the 
same way as the correction of hypothyroidism, by slowly titrating the 
dose up to normal over 3 months. 
Contraindications to Testosterone Therapy
The main contraindications to T therapy are a haematocrit >54%, male 
breast cancer, locally advanced or metastatic prostate cancer, an 
active desire to have children (T therapy reduces spermatogenesis) 
and severe CHF (NYHA class IV).1,21 
Additional contraindications include an unevaluated prostate nodule or 
induration, prostate specific antigen >4 ng/ml (or >3 ng/ml in those at high 
risk of prostate cancer), severe untreated sleep apnoea and severe lower 
urinary tract symptoms associated with benign prostatic hyperplasia.1,3,22,24
Discussion
Both ED and TD are now regarded as independent CV risk factors.94–96 
ED is common in cardiac patients and virtually all international 
guidelines recommend testing for TD in men with ED.97
PDE5 inhibitors are first-line therapy for men with ED.98 Patients 
unresponsive to PDE5 inhibitors may be rescued with T therapy, 
especially if their T level is less than 8 nmol/l.99 
The Birmingham, Lichfield, Atherstone, Sutton and Tamworth (BLAST) 
study found that in patients with T2D, T therapy, PDE5 inhibitors 
and statin therapy appeared to be synergistic and independent in 
preventing morbidity and mortality. T therapy and PDE5 inhibitors 
were independently associated with reduced all-cause mortality, 
with the greatest benefit from both treatments being seen in 
older men.71,72
Evidence also suggests that PDE5 inhibitors improve insulin 
sensitivity.100,101 These findings of reduced mortality in men taking PED5 
inhibitors are in close agreement with Anderson et al., who followed up 
5,956 UK men with T2D over 6.9 years. A 31.0% reduction in all-cause 
mortality and a 26.0% reduction in MI were reported with a low rate of 
PDE5 inhibitor prescribing at 22.8%.73
PDE5 inhibitors protect against endothelial reperfusion injury, improve 
endothelial function and reduce systemic and pulmonary blood 
pressure.101 Andersson et al. followed up 43,415 Swedish men after 
first MI for 5 years and found a significant reduction in all-cause and 
CV mortality and a 30% reduction in new diagnoses of heart failure and 
related admissions in men prescribed PDE5 inhibitors.74 T levels were 
not recorded and the benefits of PDE5 inhibitors appeared dose related 
and were not seen with other treatments for ED.
An assessment of CV risk is inadequate and inaccurate if a question 
regarding ED is not included in the risk calculation, as in QRISK®3.95 
Conclusion
The balance of evidence is that T therapy does not increase CV risk. 
Many studies have demonstrated that a low serum T concentration is 
associated with increased CV risk and mortality and that T therapy may 
have clinically relevant CV benefits.
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Figure 5: Mortality of Men with Type 2 Diabetes Not 
Receiving Phosphodiesterase Type 5 Inhibitors 
Mortality data of men with type 2 diabetes who were not receiving phosphodiesterase 
type 5 inhibitors followed for approximately 4 years (n=682). Source: Hackett et al. 2016.72 
Reproduced with permission from Wiley.
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Evidence demonstrates reduced CV risk with a higher endogenous T 
concentration, evidence of improvement of known CV risk factors with 
T therapy and reduced mortality in T deficient men who received T 
therapy versus untreated men, evidence of improvement of myocardial 
ischaemia in men with CAD, improved exercise capacity in men with 
CHF and improvement in serum glucose levels, HbA1c and insulin 
resistance in men with diabetes and prediabetes.
Bearing these facts in mind, when dealing with cardiac patients 
clinicians need to be alert to the possibility of undisclosed sexual 
problems and underlying TD, which are amenable to treatment.
The following statements are the conclusions of the BSSM:1
• Other benefits of replacing T in deficient men are that beyond 
6 months there is evidence of benefit of T therapy in terms of 
body composition, features of the metabolic syndrome and bone 
mineralisation. 
• T therapy also improves sexual desire, erectile function and sexual 
satisfaction. Reductions in BMI and waist circumference, and 
improvements in glycaemic control and lipid profiles, are observed 
in hypogonadal men receiving T therapy.
• Trials of T therapy should extend beyond 6 months and maximal 
benefit is often seen after 12 months. 
• Patients should be informed about the benefits and side-effects of 
therapy to allow a joint decision regarding the appropriateness of 
treatment.
• The adverse effects of T therapy should be fully discussed and, 
where appropriate its potential effect on future fertility for each 
patient and his partner. 
• When T therapy is prescribed, it should be accompanied by weight 
loss and lifestyle advice as standard management.
• For patients who are severely symptomatic, with T levels <8 nmol/l, 
dietary and lifestyle advice alone is unlikely to produce meaningful 
improvement within a relevant clinical period. 
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